Table 1.
Population characteristics
| Whole sample (n=892) | Fever (n=44) | COVID-19 (n=10) | Deceased (n=8) | |
|---|---|---|---|---|
| Gender | ||||
| F | 785 (88%) | 40 (90.9%) | 10 (100%) | 7 (87.5%) |
| M | 107 (12%) | 4 (9.1%) | 0 (0%) | 1 (12.5%) |
| Age | 70.9 ± 11.4 | 69.1 ± 11.7 | 79.9 ± 8.1 | 84.7 ± 3.4 |
| Origin | ||||
| AV1 | 27 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| AV2 | 758 (85%) | 40 (90.9%) | 9 (90%) | 8 (100%) |
| AV3 | 72 (8.1%) | 2 (4.5%) | 1 (10%) | 0 (0%) |
| AV4 | 15 (1.7%) | 2 (4.5%) | 0 (0%) | 0 (0%) |
| AV5 | 20 (2.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Fever | 44 (5.1%) | - | 9 (90%) | 2 (25%) |
| Treatment (except vit. D) | ||||
| None | 195 (22.1%) | 10 (22.7%) | 0 (0%) | 0 (0%) |
| Denosumab | 502 (56.8%) | 28 (63.7%) | 8 (80%) | 8 (100%) |
| Teriparatide | 39 (4.4%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oral bisphosphonates | 102 (11.6%) | 3 (6.8%) | 0 (0%) | 0 (0%) |
| Intravenous bisphosphonates | 45 (5.1%) | 3 (6.8%) | 2 (20%) | 0 (0%) |
| Vitamin D | 833 (94.6%) | 39 (88.6%) | 9 (90%) | 8 (100%) |
| Diabetes mellitus | 80 (9.4%) | 6 (13.6%) | 2 (20%) | 1 (14.3%) |
| Hypertension | 454 (52.8%) | 25 (56.8%) | 4 (40%) | 5 (71.4%) |
| Heart disease | 140 (16.3%) | 6 (13.6%) | 2 (20%) | 3 (42.9%) |
| Kidney transplant | 71 (8%) | 3 (6.8%) | 0 (0%) | 0 (0%) |
| Hormone therapy for cancer | 336 (38.4%) | 18 (40.9%) | 3 (30%) | 0 (0%) |
| COVID-19 infection | 10 (1.2%) | 9 (20.9%) | - | 2 (33.3%) |
| Fractures (any) | 396 (44.8%) | 15 (34.1%) | 4 (40%) | 7 (87.5%) |
| Fractures (femoral) | 44 (5%) | 4 (9.1%) | 1 (10%) | 0 (0%) |
| Fractures (vertebral) | 364 (41.3%) | 16 (36.4%) | 3 (30%) | 7 (87.5%) |
| Fractures (other) | 99 (14.3%) | 11 (34.4%) | 5 (83.3%) | 3 (50%) |
| Deceased | 8 (0.9%) | 2 (4.5%) | 2 (20%) | - |
| Hospitalization | 33 (3.9%) | 11 (25%) | 7 (70%) | 3 (50%) |
| Severe osteoporosis | 408 (45.7%) | 17 (38.6%) | 5 (50%) | 7 (87.5%) |